Valuation
- Market cap
- 8,401,489,000
- Revenue TTM
- $0
- Net income TTM
- $-255,840,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 5,142,000
- Avg volume
- 1,808,356
- Day's range
- $135.06 – $135.09
- Shares out
- 62,201,000
- Stochastic %K
- 95%
- Beta
- 0.33
- Analysts
- Sell
- Price target
- $134.53
Company profile
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulm...
Show more
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (650) 394-5230
- Website
- https://www.apogeetherapeutics.com
- Address
- One Letterman Drive, Building B Suites B6-850 and B6-800 The Presidio of San Francisco, San Francisco, United States
Latest news
No headlines yet.
